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Abstract
Background: Lantibiotics are small microbial peptide antibiotics that are characterized by the presence of the thioether
amino acids lanthionine and methyllanthionine. Lantibiotics possess structural genes which encode inactive prepeptides.
During maturation, the prepeptide undergoes posttranslational modifications including the introduction of rare amino acids
as lanthionine and methyllanthione as well as the proteolytic removal of the leader. The structural gene (lanA) as well as the
other genes which are involved in lantibiotic modification (lanM, lanB, lanC, lanP), regulation (lanR, lanK), export (lanT(P))
and immunity (lanEFG) are organized in biosynthetic gene clusters.
Methodology/Principal Findings: Sequence comparisons in the NCBI database showed that Bacillus licheniformis DSM 13
harbours a putative lantibiotic gene cluster which comprises two structural genes (licA1, licA2) and two modification
enzymes (licM1, licM2) in addition to 10 ORFs that show sequence similarities to proteins involved in lantibiotic production.
A heat labile antimicrobial activity was detected in the culture supernatant and a heat stabile activity was present in the
isopropanol cell wash extract of this strain. In agar well diffusion assays both fractions exhibited slightly different activity
spectra against Gram-positive bacteria. In order to demonstrate the connection between the lantibiotic gene cluster and
one of the antibacterial activities, two Bacillus licheniformis DSM 13 mutant strains harbouring insertions in the structural
genes of the modification enzymes licM1 and licM2 were constructed. These strains were characterized by a loss of activity
in the isopropanol extract and substractive MALDI-TOF predicted masses of 3020.6 Da and 3250.6 Da for the active
peptides.
Conclusions/Significance: In conclusion, B. licheniformis DSM 13 produces an antimicrobial substance that represents the
two-peptide lantibiotic lichenicidin and that shows activity against a wide range of Gram-positive bacteria including
methicillin resistant Staphylococcus aureus strains.
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Introduction
Lantibiotics (lanthionine containing antibiotics) are gene encoded,
ribosomally synthesized antimicrobial peptides. They are charac-
terized by extensive posttranslational modification reactions,
which result in the formation of the unique thioether amino acids
lanthionine and methyllanthionine as well as the dehydrated
amino acids didehydroalanine (Dha) and didehydrobutyrine (Dhb)
(for a current review see [1,2]).
According to a recently proposed classification scheme, there
are three main lantibiotic subgroups [2]. Type I lantibiotics
comprise the linear peptides that are modified by LanB and LanC
enzymes. Nisin and Pep5 are typical members of this class. Type II
lantibiotics are globular peptides with the prototype lantibiotics
mersacidin and cinnamycin that are modified by LanM enzymes.
The type III lantibiotics SapT and SapB constitute an emerging
group of lantibiotics that has mainly morphogenetic functions and
displays very limited antibiotic activities [3,4]. A further
classification of lantibiotics can be based upon their mode of
action: Some lantibiotics such as mersacidin [5] and planosporicin
[6] bind to lipid II and thereby inhibit cell wall biosynthesis in
sensitive bacteria. Other peptides attack the bacterial membrane
by pore formation as e. g. Pep5 [7]. A third group is characterized
by an ingenious double mode of action principle that combines
inhibition of peptidoglycan biosynthesis by binding and dislocation
of lipid II with pore formation in bacterial membranes. Both
functions can be combined in a single molecule (e. g. nisin or
epidermin) [8] or can be implemented in a combination of two
functionally specialized peptides as shown for lacticin 3147 that is
produced by Lactococcus lactis. In such two-peptide lantibiotics, the
globular a-peptide with homology to mersacidin binds to lipid II
and then forms a complex with the elongated b-peptide.
Subsequently the b-peptide forms a pore in the bacterial
membrane [9,10].
In contrast to other peptide antibiotics, lantibiotics are gene
encoded [1,2]. The structural genes are usually found in
biosynthetic gene clusters and encode prepeptides that consist of
an N-terminal leader sequence that is typically separated by a
conserved G(G/A/S) cleavage site from the propeptide,which is the
precursor of the mature lantibiotic. The propeptide contains Ser,
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6788Thr and Cys residues that are later modified to yield the lanthionine
and methyllanthionine residues. The enzymes involved in these
modification reactions are either LanM enzymes, that catalyse both
reactions (dehydration of the hydroxy amino acids and cyclization),
or a combination of a LanB enzyme (dehydration of Ser and Thr
residues) and a LanC enzyme (thioether formation) is present.
Furthermore, many lantibiotic gene clusters contain a GG-leader
peptidase that is the N-terminal domain of an ABC-type
transporter. This protein functions in removal of the leader
sequence concomitantly to the export of the lantibiotic. In addition,
all lantibiotic gene clusters encode proteins that protect the
producer strain against the antimicrobial effect of the lantibiotic,
the so-called immunity proteins. Very often, especially with the lipid
II binding lantibiotics, the immunity proteins are exporters that
prevent binding of the lantibiotic to the bacterial membrane;
however, membrane-associated peptides or cell wall bound proteins
havealso been discovered.Regulatoryproteins areencodedinsome
but not all biosynthetic gene clusters [1,2].
We performed a data base search for new lantibiotic gene
clusters based on the conserved structure of the enzymes that are
involved in the posttranslational modification procedures. To this
end BLASTP at the NCBI database was used to find homologues
of the mersacidin modification enzyme MrsM [11], the Pep5
modification enzyme PepB [12] and the cinnamycin modifying
enzyme CinM [13] in other microorganisms, thus covering the
main lantibiotic subgroups.
Among many other gene clusters, the blast yielded a
biosynthetic gene cluster in Bacillus licheniformis DSM 13 (ATCC
14580) that encodes a lantibiotic prepeptide with apparent
homology to mersacidin [14], which is a lantibiotic with promising
anti-Staphylococcus activity [15]. For this reason, the antibacterial
activity formed by B. licheniformis DSM 13 was chosen for further
studies, especially as the absence of further polyketide (pks), pliastin
(pps) and the bacitracin biosynthesis operons was reported in this
genome. In contrast, the biosynthesis genes for lichenysin, which is
a hemolytic surfactin-like toxin with activity against Gram-positive
and Gram-negative bacteria [16] and eukaryotic cells are present
[17,18], however, failure of the strain to produce this substance
had been reported earlier [19]. Therefore, no further production
of antibiotics was expected. Here we report the identification and
antibacterial activity of the new two-peptide lantibiotic lichenicidin
and the antibacterial spectrum of an unanticipated substance that
is present in the culture supernatant.
Results
A new lantibiotic gene cluster
The type strain of B. licheniformis has been deposited in several
strain collections and the isolate of the American type culture
collection (ATCC 14580) as well as the isolate of the DSMZ have
been sequenced (DSM 13: GenBank accession No. AE017333
[17]) (ATCC 14580: GenBank accession CP000002 [18]). In the
course of annotating both genomes, a putative lantibiotic
structural gene had been noted and had been named lichenicidin
[18] or had been annotated as ‘‘putative lantibiotic mersacidin
precursor‘‘ [17], respectively. Here we adopt the locus tags of the
strain DSM 13 that was used in our experiments.
The gene cluster of lichenicidin (Fig. 1) is located on both
strands at the far end of the chromosome and covers bp 3938843
to 3953096 (BLi04116 to BLi04128) in a total of 4222748 bp. The
GC content (45.1%) of the cluster is quite similar to the average
GC content of the whole genome (46.2%) [17] and the gene
cluster does not seem to be associated with any mobile element.
Two genes, BLi04126 (34% amino acid sequence identity to
HalM2 [20] and BLi04128 (34% identity to HalM1 [20], 33%
identity to MrsM [11]) encode the modifying enzymes that were
recognised during the data base search using MrsM. In between,
one structural gene BLi04127 was annotated that encodes the
lantibiotic prepeptide (see above) with similarity to mersacidin
(40%) [14] and HalA1 (38%) [21], which belong to the class II
lantibiotics as well as other a-peptides of two-peptide lantibiotics
(Fig. 2a). However, the presence of two modification enzymes
indicates the presence of a second, dissimilar prepeptide as seen in
the gene clusters of lacticin 3147 [22], haloduracin [20] and
staphylococcin C55 [23]. Lantibiotic structural genes can be
identified by Cys/Ser/Thr residues in the C-terminus of the
prepeptides and their conserved cleavage sites. Indeed, upon closer
analysis upstream of the structural gene a second structural gene,
that had been overlooked during annotation in both available
sequences, was found to be located 8 bp downstream of an
AGGAGG Shine- Dalgarno sequence, encoding a 72 amino acid
(aa) prepeptide (bp 3949269–3949514) and consisting of a leader
of 34 aa and a propeptide of 38 aa. This prepeptide shows
similarity to the haloduracin b-peptide HalA2 (52%) [21], i. e. a
gene which encodes a peptide with an elongated structure; the
similarities to the other b-peptides of two-peptide systems were
lower, ranging from 11% (CylLL) [24] to 30% (LtnA2) [22]
(Fig. 2b). The presence of this gene was also suggested in a recent
publication [21]. Further downstream BLi04125 constitutes a
transporter with a peptidase subunit and 49% similarity to
HalT(P) [20], and BLi4124 encodes a protein with an N-terminal
signal domain that shows similarity to a peptidase involved in
processing of the lantibiotic cytolysin (CylA, 37%) and a peptidase
encoded in the genome of B. halodurans C-125 (BH1491, 49%)
[25]. BLi04123 is a small hypothetical protein. BLi04122
constitutes a helix-turn-helix protein that shows 60% similarity
to a protein that is encoded near the haloduracin gene cluster
(BH0460) and may be involved in regulation. BLi04121 is a small
Figure 1. The lichenicidin gene cluster. The genes of the prepeptides are black; the genes of the two modification enzymes are grey. The other
genes are marked with the following patterns: processing transporter, vertical stripes; the peptidase gene, checkerboard pattern; the putative
regulator gene, horizontal stripes; genes that might be involved in immunity and encode proteins that have similarity to transporters, dots. The
numbers give the last two digits of the locus tags in the annotation of the B. licheniformis DSM 13 isolate. For the small white orfs, no functions could
be assigned so far, however similar orfs are encoded in the vicinity of the haloduracin gene cluster.
doi:10.1371/journal.pone.0006788.g001
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of the haloduracin gene cluster (BH0459) [25] and harbors three
transmembrane helices. The following orfs might be involved in
immunity against the lantibiotic: BLi04120 is the ATP binding
domain of an ABC transporter. BLi04119 does not show any
sequence similarity to known proteins, however, six transmem-
brane sequences are predicted for this protein. BLi04118 shows
low similarity to the MrsE protein of the mersacidin gene cluster
(21%) [26] and likewise, a computer analysis shows six membrane
spanning regions. The N-terminal two thirds of BLi04117 appear
homologous to the bacitracin transporter of B. licheniformis,a
protein that is able to prevent the binding of bacitracin to
undecaprenyl-pyrophosphate [27], to the ATPase component of
the CcmA multidrug resistance system and to the ATPase subunit
of the haloduracin gene cluster HalF1 (35.8%) [20]. BLi04116
again is a transmembrane protein with six membrane spanning
helices and similarity to BcrB (52%). The following gene
downstream encodes a protein with similarity to the ferrochelatase
HemH, indicating that the gene cluster ends here. Upstream the
gene cluster is bordered by BLi04129, encoding a pectate lyase. In
conclusion, this gene cluster represents 14 Orfs, with two
lantibiotic structural genes, two modification enzymes, a peptidase,
one regulator and probably two different immunity systems (an
ABC transporter BLi04120-BLi04118 and a transporter with
homology to the bacitracin transporter BLi4117/BLi4116). After a
search of both annotated sequences for ‘‘free’’ gene designations
we propose according to established lantibiotic gene nomenclature
the following gene designations for the ORFs involved in
biosynthesis of lichenicidin: licA1 (BLi04127, the structural gene
of the mature a-peptide Lica), licA2 (the structural gene of the
mature b-peptide Licb); licM1 (BLi04128 encoding the LanM that
modifies LicA1), licM2 (BLi04126 encoding the LanM modifying
LicA2), licT(P) (BLi04125 encoding the processing transporter)
and licP (BLi04124 encoding the peptidase).
B. licheniformis produces at least two antibiotic
substances
First production experiments and activity tests with crude
supernatant in synthetic medium (26BPM), tryptic soy both,
lysogeny broth (LB) and Mueller Hinton broth confirmed that B.
licheniformis DSM 13 indeed produced an antibacterial activity that
affected the growth of Gram-positive bacteria as Bacillus subtilis,
Micrococcus luteus, Staphylococcus aureus, Streptococcus pyogenes, Staphylo-
coccus simulans and enterococci but neither caused hemolysis nor
inhibited the growth of Gram-negative bacteria. Furthermore, the
isopropanol wash extract of the cell pellet from 26BPM was also
Figure 2. Amino acid alignments of two-peptide lantibiotics. (A) Amino acid sequence alignment of the LicA1 propeptide with the LanA1
propeptides of the two-peptide lantibiotics plantaricin (PlwA1, AAG02567), staphylococcin C55 (SacA1, BAB78438), lacticin 3147 (LtnA1, O87236),
haloduracin (HalA1, BAB04173), BHT (BhtA1, AAZ76603) and Smb (SmbA1, BAD72777) and, for comparison, the propeptide of mersacidin (MrsA,
Z47559). Amino acid identities of the LanA1 propeptides are highlighted in green (100%), pink (75%) and blue (35%). The thioether bridging pattern
represents that of the Hala and Plwa peptide. (B) Amino acid sequence alignment of the LicA2 propeptide with the Lanb/LanA2 propeptides of the
two-peptide lantibiotics plantaricin (PlwA2, AAG02566), staphylococcin C55 (SacA2, BAB78439), lacticin 3147 (LtnA2, O87237), haloduracin (HalA2,
BAB04172), BHT (BhtA2, AAZ76602) and Smb (SmbA2, BAD72776). Amino acid identities are highlighted in green (100%), pink (75%) and blue (35%).
The thioether bridging pattern represents that of the Halb and Plwb peptides.
doi:10.1371/journal.pone.0006788.g002
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positive bacteria including several methicillin resistant Staphylococ-
cus aureus (MRSA) strains, however with a slightly different
spectrum of activity, indicating that the culture supernatant and
the isopropanol cell wash extract might contain different
substances (Fig. 3). Gram-negative bacteria and eukaryotic cells
were not affected (data not shown).
A further characterization of both active fractions showed that
the supernatant contained a substance displaying only limited heat
stability that was inactivated within two hours by 80uC and within
30 min by boiling, whereas the activity in the isopropanol extract
was fully heat stable and withstood 4 h at 100uC without any
losses. Both active fractions caused inhibition of growth of the
indicator strain M. luteus in a deferred antagonism test at pH 1.5, 3
and 9, however, the supernatant did not show any antibacterial
activity at pH 13. In contrast, the isopropanol cell extract was
initially active but inactivated after 4 h at pH 13. Incubation in
the presence of proteolytic enzymes (pronase E, proteinase K,
trypsin, chymotrypsin) did not affect the antibacterial activity
present in the supernatant. The isopropanol extract was also stable
in the presence of trypsin and chymotrypsin, however, addition of
proteinase K and pronase E led to inactivation within 4 h of
incubation, indicating the proteinaceous nature of this substance
(Fig. 4). Cross resistance of B. halodurans C-125, which produces
the closely related two-peptide lantibiotic haloduracin [21], was
also tested, however, B. halodurans C-125 was sensitive to both
fractions. The same result was obtained with the producer of
mersacidin, Bacillus spec. HIL Y-85,54728 [28].
Inactivation of the lantibiotic modification enzymes
In order to correlate the antimicrobial activity with the presence
of the putative lantibiotic gene cluster, the biosynthetic enzymes
LicM1 (BLi04128) and LicM2 (BLi04126) were both inactivated
by insertion of a vector that carried two fragments of the gene
employing the temperature sensitive plasmids pMADDelLic-
M1AC and pMADLicM2AC, respectively. Based on the vector
pMAD, these plasmids harbor the bgaB gene (blue white selection),
the ermC gene (erythromycin-resistance) and the 59 region and 39
regions of the genes licM1 or licM2 lacking the start and stop
codons. Both plasmids were introduced in B. licheniformis MW3, a
transformable strain of B. licheniformis DSM 13, since the producer
strain is characterized by loss of natural competence and a very
active restriction system [29]. Insertion mutants harboured two
copies of the LanM enzyme in their genome. The transcribed copy
of licM1 which is located downstream of licA1 harbours an internal
deletion that leads to a loss of 718 aa. The second copy is located
downstream of the bga gene on the opposite strand and does not
dispose of promoter, Shine-Dalgarno sequence and start codon.
The first copy of licM2 leads to transcription of a protein with a C-
terminal deletion of 873 aa and the second copy again cannot be
transcribed. Furthermore, integration of the plasmid into
BLi04126 was expected to exert a polar effect and inhibit
transcription of the downstream genes of the gene cluster i. e. of
the transporter and peptidase that are probably involved with
export and processing of both peptides (Fig. 5).
After inactivating the modifying enzyme of LicA1, the LicM1
insertion mutant was characterized by a loss of activity of the
isopropanol cell wash extract against M. luteus. In contrast, the
activity of the culture supernatant was not affected. MALDI-TOF
mass spectrometry showed the loss of a peak at 3251.7 Da
(m+1H)
1+ in the isopropanol wash extract of this mutant (Fig. 6a/
b). After removal of the leader at the conserved GG cleavage site,
the unmodified propeptide LicA1 possesses a calculated molecular
mass of 3376.9 Da. Therefore, the missing peak might correspond
to the mature Lica where seven of eight possible dehydrations
have taken place (2126 Da) during the posttranslational
modification reactions.
Furthermore, all antibacterial activity in the isopropanol cell
wash extract was also lost in the LicM2 integration mutant. The
antibacterial activity in the culture supernatant remained unaf-
fected, indicating that this activity is definitely not related to the
lantibiotic gene cluster. The MALDI-TOF spectrum of the cell
wash extract lacked the peaks [(m+1H)
1+] at 3251.7 Da as well as
at 3021.7 and a minor peak at 3039.6 Da that was present in some
preparations indicating a correlation of all three masses to the
lichenicidin gene cluster (Fig. 6c). The calculated mass of the
unmodified propeptide LicA2 amounts to 3905.3 Da. A mass of
3020.6 Da can be predicted for a Licb peptide that has lost the six
N-terminal amino acids by proteolytic processing and harbors 12
dehydrated residues and three hydroxy amino acids. A mass of
3038.6 Da would correspond to a peptide with only 11
dehydrations. The N-terminal processing also leads to the loss of
two negatively charged residues (Asp and Glu), resulting in a
positive net charge for Licb, which is characteristic for membrane
active peptides. None of the three masses was present in the
spectra of the culture supernatant.
In order to show that the lost masses corresponded to the
antibacterial activity, the isopropanol cell wash extract was
fractionated by HPLC on a Poros column and the masses of the
active fractions were determined. As shown in Fig. 7 the masses
for Lica (fraction 9) and Licb (fraction 10–13) were associated with
the active fractions confirming that these peptides represent the
two-peptide lantibiotic lichenicidin. A combination of fraction 9
and fraction 11 (25 ml of each fraction) showed enhanced activity,
indicating a synergistic action of both peptides (Fig. 8).
Because the lantibiotic seemed to be present only in the cell wall
associated form, culture supernatant, that contained protease
activity as determined on skim milk agar plates, was incubated
with the isopropanol wash extract in order to test the protease
stability of lichenicidin. After 2 hours of incubation, the activity
against S. aureus ATCC 33592 or S. gallinarum (data not shown) was
not diminished, indicating that the peptides are indeed protease
resistant (Fig. 9).
Antibiotic efficacy of lichenicidin against MRSA
In order to compare the antibiotic efficacy of lichenicidin
against MRSA strains to that other lantibiotics, we tested solutions
containing lichenicidin, mersacidin, Pep5 and nisin against S.
aureus SG511 (sensitive laboratory strain - MSSA), S. aureus ATCC
33592 (MRSA) and S. aureus LT440/09 (cMRSA). All lantibiotics
had to be employed at higher concentrations to inhibit growth of
the MRSA strains than for the MSSA; the minimum inhibitory
concentrations on agar plates were 1.8360.41-fold (ATCC 33592)
or 2.6761.03-fold (LT440/09) higher for nisin, 4.861.6-fold
(ATCC 33592) and 4.761.6-fold (LT440/09) higher for mersa-
cidin, 8-fold (ATCC 33592) and 7.3361.63-fold (LT440/09)
higher for lichenicidin and 18.766.5-fold (LT440/09) or
26.668.26-fold (ATCC 33592) higher for Pep5 than the minimum
inhibitory concentrations against S. aureus SG511.
Discussion
Potential applications for lantibiotics are food conservation and
novel therapeutics. An obstacle that has hampered the medical
application of many lantibiotics is their missing resistance to the
proteases; this is especially characteristic for the elongated pore-
forming peptides like nisin [30], epidermin [31] and Pep5 [32].
These peptides possess a hinge region which is essential for pore-
Lichenicidin a New Lantibiotic
PLoS ONE | www.plosone.org 4 August 2009 | Volume 4 | Issue 8 | e6788Figure 3. Agar well diffusion assays of the B. licheniformis DSM 13 culture supernatant and the isopropanol extract. The culture
supernatant (green bars) as well as the isopropanol extract (blue bars) were active against Gram-positive bacteria but showed slightly different
spectra of activity, indicating that supernatant and isopropanol cell wash extract contained different antibacterial compounds.
doi:10.1371/journal.pone.0006788.g003
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chymotrypsin or trypsin. Stabilization of Pep5 by a further ring
structure prevented chymotrypsin activity, however, the antibac-
terial activity was also decreased [32]. In contrast, those peptides
that are characterized by formation of intertwined rings and do
not have elongated linear stretches show higher protease resistance
as for example mersacidin. One reason that B. licheniformis DSM 13
was chosen for further investigations is that it is most prominent in
protease production. Seven protease genes are annotated in the
genome of this strain (BLi00340, BLi04019; BLi01123; BLi02863;
BLi02862, BLi01109, BLi01909) among them Subtilisin Carls-
berg, a protease that is employed in detergents [17]. Therefore, the
antibacterial activity excreted by this strain was expected to show
higher protease resistance than lantibiotics produced by members
of the genera Staphylococcus and Lactococcus.
Closer inspection indicated that this gene cluster might encode a
two-peptide lantibiotic with similarity to haloduracin. So far seven
two-peptide antibiotics have been described [21,33–38], for a
review see [39]. With the exception of the Lys in the third ring
(and this position is taken by His in some other peptides), all amino
acids found in Lica are present in at least one other peptide of the
group (Fig. 2a). The masses indicate that one residue of LicA1
escapes dehydration and this might be the residue that is not
dehydrated in haloduracin [40], the Ser in the C-terminal ring
structure. In addition, the location of the ring forming and other
essential amino acids, i. e. the LanA1 motif, is conserved for the
terminal three rings, indicating that the C-terminal ring structure
of Lica might be identical to that of the other a-peptides with a
solved structure (lacticin 3147 [41] and haloduracin [40]). This
close similarity does not extend to the N-terminus of the peptide,
where, just as in mersacidin, a fourth (Me)Lan might be formed,
since a Cys and several didehydro amino acids are present.
As with LicA1, the LanA2 motif is conserved in LicA2 (Fig. 2b),
indicating that the three C-terminal rings might be formed as in
Figure 4. Stability assay: Treatment with proteases. No loss of both antimicrobial activities was detected after treatment with trypsin and
chymotrypsin for 4 h for both extracts. However, incubation of the isopropanol cell wash extract (blue bar) with proteinase K and pronase E resulted
in a total loss of activity against M. luteus while the antimicrobial activity of the culture supernant (green column) was unaffected by these proteases.
doi:10.1371/journal.pone.0006788.g004
Figure 5. Gene inactivation of the lantibiotic modifications enzyme LicM1 (A) and LicM2 (B) by homologous recombination. Gene
inactivations of the modifications enzymes LicM1 and LicM2 were performed by plasmid integration using the recombinant plasmids
pMADDelLicM1AC and pMADLicM2AC. The resulting insertion mutants B. licheniformis LicM1INT (A) and LicM2INT (B) harbour two copies of the
lanM genes within the lantibiotic gene cluster: a copy that is transcribed but is truncated and a second copy that does not dispose of promoter, Shine
Dalgarno sequence and start codon. Genes that derive from the plasmid pMADDelLicM1AC are marked in green colours and those deriving from
pMADLicM2AC are marked in orange and red.
doi:10.1371/journal.pone.0006788.g005
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peptides and contains several hydroxy amino acids. In addition,
the Licb peptides are characterized by a mass that is consistent
with 11 and 12 of 15 possible dehydrations and an N-terminal
processing of six amino acids. An N-terminal processing has also
been demonstrated for Halb [40] which is characterized by an N-
terminal disulfide ring structure. The protease encoded by
BLi4124 contains a secretion signal and might well be involved
here. The loss of six N-terminal amino acids places a Thr residue
at the N-terminus of Licb, thereby enabling an N-terminal MeLan
ring, which would inhibit any further protease activity. The
resistance of the antibacterial activity in the extract to digest with
chymotrypsin strongly indicates the presence of such a fourth ring
structure in the N-terminus since there is a cleavage site
(TTPATTSSWQTC) located in this area. However, the N-
terminus contains six hydroxy amino acids that might serve for the
formation of an N-terminal ring structure, so that further
structural analysis is required in order to judge the size of the
ring. A possible proteinase K cleavage site is located in the linear
region of the peptide (ITAQGVTV) and might account for the
loss of activity seen with this enzyme.
In conclusion, this study shows that B. licheniformis DSM 13
produces a novel two-peptide lantibiotic that is associated with the
cell surface and that shows stability against trypsin, chymotrypsin
and the proteases of the culture supernatant of the producer.
Remarkably, the antibacterial spectrum of lichenicidin showed a
good activity against a range of MRSA strains that cause
problematic infections in the hospital setting. The test panel
included clinical isolates of epidemic strains that are currently
widespread in Germany. A second substance with activity against
Gram-positive bacteria is present in the culture supernatant. Lack
of hemolytic activity and the activity spectrum indicate that this
substance does not represent lichenysin [16], so that its origin in
the genomic context remains unclear. Lichenysin itself was not
produced although the biosynthesis genes are present in the strain.
The failure of lichenysin production here [19] might be due to the
fact, that transcription of the biosynthetic machinery of lichenysin
is activated by the phosphorylated form of ComA [42]. However,
the gene of the kinase ComP necessary for activation of ComA
[43] has suffered insertion of an IS element in B. licheniformis DSM
13 [18].
The other open question regards the localization of lichenicidin
in the cell wash extract. A location in the cell wall of the producer
strain has also been described for the haloduracin [20] and lacticin
peptides. For the lacticin peptides, mutant studies indicated that
the LtnA2 peptide might be tethered to the cell wall via the LtnA1
peptide [44]. Furthermore, the diffusion of the lichenicidin
peptides might be restricted by capsule formation: Both mature
peptides carry a positive net charge (Lica +1, Licb +2). B.
licheniformis is able to produce a glutamyl polypeptide capsule [18].
Figure 6. MALDI-TOF mass spectra of the B. licheniformis MW3 wild type (A) and its insertion mutans LicM1INT (B) and LicM2INT (C).
The isopropanol extracts of the insertion mutants B. licheniformis LicM1INT and LicM2INT were characterized by the loss of activity against M. luteus.
MALDI-TOF spectra of these isopropanol extracts in comparison to the wildtype (A) showed the loss of a peak at 3251 Da in the case of the LicM1
insertion mutant (B) indicating that this peak represents the protonated form of the active Lica peptide. The insertion of a plasmid into the gene of
the modification enzyme LicM2 inactivated this enzyme and most probably exerted a polar effect on the downstream genes, thus affecting
production of both peptides. This mutant did not produce the Lica peptide and is further characterized by the absence of a 3021 Da peak, which
might represent the protonated form of the mature Licb peptide, harboring 12 dehydrated residues (C). In some cultivations a further peak of 3039
Da was observed, which probably denotes a Licb peptide with only 11 of 15 possible dehydrations.
doi:10.1371/journal.pone.0006788.g006
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641, on nisin containing agar plates led to selection of nisin
resistant mutants with increased capsule formation (Bierbaum,
unpublished results), which indicates that the capsule might indeed
inhibit the diffusion of or bind cationic lantibiotics. However, such
a location seems inappropriate, considering that the overwhelming
majority of lantibiotics is regarded as bacteriocins. These
molecules function in the defense of the producer strain. To this
end, the peptides would have to be present in the medium. On the
other hand, the morphogenetic peptides of Streptomyces are
lantibiotics, too [45], and the genomic sequences that recently
appeared in the databases have shown that lantibiotic biosynthesis
genes are widespread among bacteria. In this context, these results
might indicate that other functions for lantibiotics in the
morphogenesis or metabolism of the producer strain may be
possible and that we are only just starting to learn about why
bacteria produce these fascinating peptides.
Materials and Methods
Bacterial strains, culture media, growth conditions and
detection of antibacterial activity
The producer strain Bacillus licheniformis DSM 13 was purchased
from the German Collection of Microorganisms and Cell Cultures
(DSMZ, Braunschweig, Germany). A transformable variant of B.
licheniformis DSM 13, the MW3 strain, was kindly provided by Prof.
Meinhardt (Institute of Molecular Microbiology and Biotechnol-
ogy, University of Mu ¨nster) [29]. Both B. licheniformis strains were
grown aerobically in tryptic soy broth or on tryptic soy agar
(Oxoid, Hampshire, Great Britain). For the detection of lantibiotic
production the producer and its mutants were cultured in two-fold
Bacillus production medium (26BPM) [46]. Escherichia coli SCS110
was used as intermediate cloning host and was cultured in
Lysogeny Broth (LB) medium at 37uC. For antibiotic activity
testing the following indicator strains were used: Bacillus cereus
DSM 31, Bacillus halodurans DSM 18197, Bacillus megaterium KM
(ATCC 13632), Bacillus subtilis 168 (DSM 402), Bacillus spec. HIL
Y-85,54728 [28], Enterococcus faecium BM 4147–1 [47], Enterococcus
faecium L4001, Lactobacillus sake 790 E2, Lactococcus lactis NCTC
497, Micrococcus luteus DSM 1790, Micrococcus luteus ATCC 4698,
Staphylococcus aureus ATCC 33592 (MRSA), S. aureus ATCC 29213
(MSSA), S. aureus 1450/94 (Northern German epidemic strain,
German Reference Centre for Staphylococci, Wernigerode,
Germany), S. aureus Cowan (ATCC 12598), S. aureus Newman
(NCTC 8178), S. aureus SG511 [48], S. aureus Wood 46 (ATCC
10832), Staphylococcus carnosus TM300 [49], Staphylococcus gallinarum
Tu ¨ 3928 [50], Staphylococcus saprophyticus DSM 20229, Staphylococcus
simulans 22 [51], and the following clinical isolates: S. aureus
LT440/09 (community acquired MRSA), S. aureus LT420/09
(MRSA), S. aureus LT819/09 (MRSA, Rhine-Hessen epidemic
strain), Enterococcus faecalis, Streptococcus agalactiae and Streptococcus
Figure 7. HPLC chromatogram of the Bacillus licheniformis
isopropanol extract. The isopropanol extract was applied to a POROS
RP-HPLC column and eluted in a gradient of 20% to 55% acetronitrile
(containing 0.1% TFA). Maldi-TOF analysis of active fractions [+ medium
activity, ++ strong activity and (+) poor activity] showed the presence of
masses representing the Lica peptide or the Licb peptide.
doi:10.1371/journal.pone.0006788.g007
Figure 8. Synergistic effect of fractions containing the Lica and
Licb peptides. 25 ml of HPLC fractions that contained the Lica peptide
or the Licb peptide as seen in mass spectrometry were tested separately
and in combination against M. luteus. Only the combination of both
peptides showed an antimicrobial activity indicating that Lica and Licb
are required for an optimal effect.
doi:10.1371/journal.pone.0006788.g008
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overnight, mixed with sterile glycerol (final concentration of 50%
v/v) and stored at 270uC.
For selective media, antibiotics (Sigma-Aldrich, Taufkirchen,
Germany) were added at the following concentrations: ampicillin
(40 mg/l) for E. coli and erythromycin (25 mg/l) for B. licheniformis
strains.
For the comparison of the antibacterial efficacy of lichenicidin
to other lantibiotics, Pep5 [52] and nisin [53] were purified as
described previously, and mersacidin was obtained from Sanofi-
Aventis (Frankfurt, Germany). Serial dilutions of the lantibiotics
and the isopropanol wash extract were prepared in half-
concentrated Mu ¨ller-Hinton broth. Fresh colonies of all indicator
organisms were used to prepare cell suspensions of about 5610
6
colony forming units per ml which were employed to inoculate
Mu ¨ller Hinton agar plates. Ten ml of the lantibiotic solutions were
spotted onto the indicator plates. The highest dilution yielding a
clear inhibition zone on the lawn was detected by visual inspection
after incubation overnight.
Detection of antimicrobial and protease activity
The detection of antimicrobial activity was performed by agar
well diffusion assays on Mu ¨ller-Hinton agar II plates (Difco
TM,
Detroit, USA) seeded with an indicator strain in wells with a
diameter of 7 mm employing 50 ml of sample unless indicated
differently [54]. After incubation at 37uC overnight, the growth
inhibition zones were measured.
The protease activity in the cell-free culture supernatants was
detected onskimmilkagarplates(3 g/l yeastextract,5 g/lpeptone,
2.5 g/l skim milk powder, 15 g/l agar, pH 7.2). 50 ml of the culture
supernatant were applied to wells (7 mm). After incubation at 37uC
overnight, the plates wereinspectedfortheformationofclear zones.
DNA and Plasmid preparation
Genomic DNA was prepared using the PrestoSpinD Kit
according to the recommendations of the supplier (Molzym,
Bremen, Germany). Plasmid DNA was isolated using the Gene-
JET
TM Plasmid Miniprep Kit (Fermentas, St. Leon-Rot, Germany).
Inactivation of the lantibiotic modifying enzymes LicM1
and LicM2
The inactivation of the lantibiotic modifying enzymes LicM1
and LicM2 was performed by plasmid integration using the
thermosensitive shuttle vector pMAD [55]. In pMADDelLic-
M1AC the vector carries the 59 and 39 parts (each 500 bp) of the
gene bli04128 (licM1) lacking the start and the stop codon. The
fragments were generated via PCR using the Phusion Polymerase
(2 u/ml, NEB, Beverly, USA) and the oligonucleotide pair
forDLicM1fragmentA and revDLicM1fragmentA for the amplifi-
cation of the 59 part and the primer pair forDLicM1fragmentC
and revDLicM1fragmentC for the 39 part of the licM1 gene
(table 1). The PCR products were purified using the MinElute
PCR Extraction Kit (QIAGEN, Hilden, Germany) and digested
with the FASTdigest
TM enzymes MluI, BglII and BamHI following
the manufacturers’ instructions (Fermentas, St. Leon-Rot, Ger-
many). Both fragments were ligated (T4 ligase, 5 u/ml, Fermentas,
St. Leon-Rot, Germany) in tandem into the corresponding
restriction sites of pMAD. The resulting vector pMADDelLic-
M1AC was introduced into E. coli SCS110 as intermediate cloning
host by electroporation (Bio-Rad, Munich, Germany).
According to this protocol, a second derivative of pMAD called
pMADLicM2AC was generated for the inactivation of the LicM2
enzyme. The 39 and 59 parts of the gene bli04126 were amplified
using the primer pairs forDelLicM2A and revDelLicM2A and
forDelLicM2C and revDelLicM2C (see table 1). Integrity of the
plasmids was confirmed by sequencing of the inserts (Sequiserve,
Vaterstetten, Germany). The recombinant vectors pMADDelLic-
M1AC and pMADDelLicM2AC were then introduced in B.
licheniformis MW3 via protoplast transformation [29] and transfor-
m a n t sw e r es e l e c t e da t3 0 uC. Recombinants that had inserted the
plasmids into the genomes were selected after cultivation overnight
at the nonpermissive temperature (45uC) in TSB (EM 25 mg/l) and
subsequentplatingon TSAagarplates(EM25 mg/l).Theinsertions
of the vectors into the target genes were confirmed by PCR using
primers that anneal withinthe genome sequence and flank the target
genes (forhomRecLicM1, revhomRecLicM1, forhomRecLicM2,
revhomRecLicM2) as well as a primer that anneals within the
vector sequence (pMADmcs2neu) (Table 1). The resulting insertion
strainswere namedB.licheniformisMW3LicM1INTandLicM2INT.
Production and peptide preparation
For lantibiotic production Bacillus licheniformis DSM 13 and MW3
were cultured in 50 ml 26BPM at 37uC with agitation. The
production experiments with the Bacillus licheniformis MW3 insertion
mutants LicM1INT and LicM2INT were performed at 45uC. After
48 hours of incubation the cells were pelleted by centrifugation at
10,0006g and 4uC for 30 minutes. For further analysis the culture
supernatant was sterilized by filtration and stored at 220uC. The
cell pellet was washed with 35 ml 70% isopropanol (adjusted to
pH 2 with HCl) and incubated at 4uC for four hours under stirring
[44]. The cells were removed by centrifugation and the supernatant
wassterilized by filtrationand stored at 220uC. ForHPLC analysis,
the isopropanol was removed by rotary evaporation (Rotavapor
Re11, Essen, Germany). Two ml of extract containing 0.1%
trifluoroacetic acid (TFA, Sigma-Aldrich, Taufkirchen, Germany)
was applied to a Poros RP-HPLC-column (10R2, 10064.6 mm,
Figure9. Co-incubation oftheisopropanol cell wash extract and
the culture supernatant. In agar well diffusion assays, the isopropanol
extract (25 ml) showed an antimicrobial activity against S. aureus ATCC
33592 (blue bar) while the culture supernantant was inactive (see also
Fig. 3). In order to test protease stability of the isopropanol extract, 25 ml
of extract were mixed with 25 ml of culture supernatant (blue-green
patterned bar), incubated for 2 h and then tested by agar diffusion. The
co-incubation of both extracts had no effect on the activity of the
isopropanol extract, indicating that the antimicrobial substance is stable
against the proteases excreted by the producer strain.
doi:10.1371/journal.pone.0006788.g009
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of 20% to 55% acetonitrile (containing 0.1% TFA). The peaks were
detected measuring the absorbance at 230 and 260 nm. The
fractions were collected and assayed for the antimicrobial activity
against M. luteus ATCC 4698 in agar well diffusion assays as well as
analyzed by MALDI-TOF spectrometry.
Stability assays
The thermal stability of the antimicrobial compounds was
analyzed by incubating 2 ml of the culture supernatant and the
isopropanol cell wash extract at 37uC, 45uC, 65uC, 80uC and
100uC for 240 min. The stability of the antimicrobial activities
against the treatment with proteases was determined by adding
10 mg/ml of proteinase K (Sigma-Aldrich, Taufkirchen, Ger-
many), pronase E (Merck, Darmstadt, Germany) a-chymotrypsin
(Sigma-Aldrich, Taufkirchen, Germany) and trypsin (Serva,
Feinbiochemica, Heidelberg) to the cell-free supernatant and the
isopropanol cell wash extract after evaporation of isopropanol and
incubating at 37uC for 240 min. The influence of pH on the
antimicrobial activity was examined by adjusting the pH to 1.5, 3,
9 and 13 and incubating for 30 minutes at room temperature. The
residual antimicrobial activities were then determined in agar well
diffusion assays against M. luteus ATCC 4698.
Mass spectrometry analysis
The mass spectrometry analysis of the peptide preparations was
performed using a MALDI-TOF mass spectrometer (Bruker Biflex,
Bruker Daltonics, Bremen, Germany). Aliquots of 1 mlo ft h e
i s o p r o p a n o lc e l lw a s he x t r a c t sw e r em i x e dw i t h2mlm a t r i x( a-cyano-
4-hydroxycinnamic acid in acetonitrile: 0.1% TFA in water, 1:3). For
MALDI-TOF analysis of the active HPLC fractions 20 mlo fe a c h
fraction were concentrated 1:10 using a rotational Vacuum
Concentrator (RVC 2–18, Christ, Osterode, Germany). The samples
were spotted onto the MALDI target and dried in air. Mass spectra
were measured in positive ion mode in the range of 1500 to 4000 Da
and analyzed by Flexanalysis 2.0 (Bruker Daltonics).
Bioinformatic tools
The GC content was determined on the Genomatix homepage
using the GEMS launcher (http://www.genomatix.de/cgi-bin/tools/
tools.pl). The potential chymotrypsin cleavage site in Licb was
observed using the Expasy PeptideCutter Tool (http://www.expasy.
ch/tools/peptidecutter/). Transmembrane sequences were identified
using the TMHMM web server v. 2.0. (http://www.cbs.dtu.dk/
services/TMHMM/). Blasts were performed at the NCBI nucleotide
website (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Subcellular localiza-
tions of the proteins were predictedu s in gt h eo n l i n et o o lCE LL Ov . 2 .5
(subCELlular LOcalization predictor, http://cello.life.nctu.edu.tw/).
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